Cardarine – GW-501516 10mg
Cardarine is presented in the ORYVION catalog as a tablet formulation containing 10mg of GW-501516 per tablet, supplied in containers of 50 tablets. Also known as GW1516, cardarine is an investigational compound that activates peroxisome proliferator-activated receptor delta (PPAR-δ).
Its mechanism of action involves regulating gene expression associated with fatty acid metabolism and energy utilization. Research has investigated its effects on metabolic pathways and lipid profiles. Cardarine is a PPAR-δ agonist, not a selective androgen receptor modulator (SARM), and these experimental findings do not establish safety or effectiveness for athletic performance.
Product Specifications:
Commercial name: Cardarine
Listed compound: GW-501516
Declared strength: 10mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Clinical development of GW-501516 was discontinued after serious toxicities, including cancers, were identified in long-term animal studies. The extent of cancer risk in humans remains uncertain, and a safe level of human exposure has not been established.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.